These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38852017)

  • 21. COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury.
    Nicosia RF; Ligresti G; Caporarello N; Akilesh S; Ribatti D
    Am J Pathol; 2021 Aug; 191(8):1374-1384. PubMed ID: 34033751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
    Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ["When it rains, it pours" - de novo diagnosed multiple myeloma with invasive Streptococcus pneumoniae infection in severe COVID-19 complicated with cytokine storm].
    Korózs D; Jenőfi N; Szabó BG; Szlávik J; Mikala G
    Orv Hetil; 2023 May; 164(20):763-769. PubMed ID: 37210715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.
    Jacobson CA; Rosenthal AC; Arnason J; Agarwal S; Zhang P; Wu W; Amber V; Yared JA
    Blood Adv; 2023 Nov; 7(21):6790-6799. PubMed ID: 37399456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
    Liu R; Lv Y; Hong F; Zhao W; Lei B; Liu J; Zhang W; He A; Wang F
    Hematol Oncol; 2023 Oct; 41(4):704-717. PubMed ID: 37186314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
    Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
    Swan D; Routledge D; Harrison S
    Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 35. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
    Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
    Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
    Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.
    Khadka RH; Sakemura R; Kenderian SS; Johnson AJ
    Immunotherapy; 2019 Jul; 11(10):851-857. PubMed ID: 31161844
    [No Abstract]   [Full Text] [Related]  

  • 40. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.